Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis

Molecular Cancer Research

Volumn 11, Issue 4, 2013, Pages 405-417

  Lee, Yu Chen ^a   Jin, Jung Kang ^b,d   Cheng, Chien Jui ^e   Huang, Chih Fen ^a,f   Song, Jian H ^b   Huang, Miao ^a   Brown, Wells S ^b   Zhang, Sui ^b   Yu Lee, Li Yuan ^c   Yeh, Edward T ^b   McIntyre, Bradley W ^b   Logothetis, Christopher J ^b   Gallick, Gary E ^b,d   Lin, Sue Hwa ^a,b,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; COLLAGEN TYPE 1; FIBRONECTIN; FOCAL ADHESION KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 33B6; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOIKIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FOLDING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD29; CELL LINE, TUMOR; EXTRACELLULAR MATRIX; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MICE; MICE, SCID; NEOPLASM METASTASIS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TRANSFECTION;

EID: 84876586639     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0551     Document Type: Article

References (55)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16. (Pubitemid 39665537)
3. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990;50:6130-8. (Pubitemid 20323663)
4. Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med 1990 322:605-12. (Pubitemid 20190796)
5. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68. (Pubitemid 350309740)
6. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-84.
7. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72. (Pubitemid 37328923)
8. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87. (Pubitemid 35283958)
9. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996;134:793-9. (Pubitemid 26269148)
10. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5:816-26. (Pubitemid 39336275)
11. Fornaro M, Manes T, Languino LR. Integrins and prostate cancer metastases. Cancer Metastasis Rev 2001;20:321-31. (Pubitemid 34595274)
12. Giancotti FG. Complexity and specificity of integrin signalling. Nat Cell Biol 2000;2:E13-4.
13. Scott LJ, Clarke NW, George NJ, Shanks JH, Testa NG, Lang SH. Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion. Br J Cancer 2001;84:1417-23. (Pubitemid 32522114)
14. Miranti CK, Brugge JS. Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol 2002;4:E83-90.
15. Assoian RK, Schwartz MA. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev 2001;11:48-53. (Pubitemid 32119277)
16. Giancotti FG, Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol 2003;19:173-206. (Pubitemid 37487347)
17. Ginsberg MH, Du X, Plow EF. Inside-out integrin signalling. Curr Opin Cell Biol 1992;4:766-71.
18. Coppolino MG, Dedhar S. Bi-directional signal transduction by integrin receptors. Int J Biochem Cell Biol 2000;32:171-88. (Pubitemid 30001820)
19. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285: 1028-32.
20. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010;11:288-300.
21. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, et al. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated inter-feron-alpha-2b and docetaxel. Cancer Res 2002;62:5720-6. (Pubitemid 35204727)
22. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 1998;77:887-94. (Pubitemid 28378138)
23. Bednarczyk JL, Wygant JN, Szabo MC, Molinari-Storey L, Renz M, Fong S, et al. Homotypic leukocyte aggregation triggered by a monoclonal antibody specific for a novel epitope expressed by the integrin beta 1 subunit: conversion of nonresponsive cells by transfecting human integrin alpha 4 subunit cDNA. J Cell Biochem 1993;51:465-78. (Pubitemid 23114279)
24. Mitchell JS, Brown WS, Woodside DG, Vanderslice P, McIntyre BW. Clustering T-cell GM1 lipid rafts increases cellular resistance to shear on fibronectin through changes in integrin affinity and cytoskeletal dynamics. Immunol Cell Biol 2009;87:324-36.
25. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, et al. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res 2008;6:1259-67.
26. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323-33.
27. Bazzoni G, Shih DT, Buck CA, Hemler ME. Monoclonal antibody 9EG7 defines a novel beta 1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium. J Biol Chem 1995;270:25570-7.
28. Lenter M, Uhlig H, Hamann A, Jeno P, Imhof B, Vestweber D. A monoclonal antibody against an activation epitope on mouse integrin chain beta 1 blocks adhesion of lymphocytes to the endothelial integrin alpha 6 beta 1. Proc Natl Acad Sci U S A 1993;90:9051-5. (Pubitemid 23306449)
29. Byron A, Humphries JD, Askari JA, Craig SE, Mould AP, Humphries MJ. Anti-integrin monoclonal antibodies. J Cell Sci 2009;122:4009-11.
30. Hall MA, Kwon S, Robinson H, Lachance PA, Azhdarinia A, Ranga-nathan R, et al. Imaging prostate cancer lymph node metastases with a multimodality contrast agent. Prostate 2012;72:129-46.
31. Burton JB, Johnson M, Sato M, Koh SB, Mulholland DJ, Stout D, et al. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med 2008;14: 882-8.
32. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002;12:89-96. (Pubitemid 34680737)
33. Fornaro M, Languino LR. Alternatively spliced variants: a new view of the integrin cytoplasmic domain. Matrix Biol 1997;16:185-93. (Pubitemid 27487660)
34. Moro L, Perlino E, Marra E, Languino LR, Greco M. Regulation of beta1C and beta1A integrin expression in prostate carcinoma cells. J Biol Chem 2004;279:1692-702. (Pubitemid 38084436)
35. Goel HL, Moro L, Murphy-Ullrich JE, Hsieh CC, Wu CL, Jiang Z, et al. Beta1 integrin cytoplasmic variants differentially regulate expression of the antiangiogenic extracellular matrix protein thrombospondin 1. Cancer Res 2009;69:5374-82.
36. Longhurst CM, Jennings LK. Integrin-mediated signal transduction. Cell Mol Life Sci 1998;54:514-26. (Pubitemid 28325625)
37. Ginsberg MH, Partridge A, Shattil SJ. Integrin regulation. Curr Opin Cell Biol 2005;17:509-16. (Pubitemid 41267165)
38. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, et al. Talin binding to integrin beta tails: a final common step in integrin activation. Science 2003 302:103-6. (Pubitemid 37210697)
39. Anthis NJ, Campbell ID. The tail of integrin activation. Trends Biochem Sci 2011;36:191-8.
40. Sakamoto S, McCann RO, Dhir R, Kyprianou N. Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res 2010;70:1885-95.
41. Lai MT, Hua CH, Tsai MH, Wan L, Lin YJ, Chen CM, et al. Talin-1 overexpression defines high risk for aggressive oral squamous cell carcinoma and promotes cancer metastasis. J Pathol 2011;224: 367-76.
42. Chandrasekaran S, Guo NH, Rodrigues RG, Kaiser J, Roberts DD. Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by alpha3beta1 integrin and regulated by insulin-like growth factor-1 and CD98. J Biol Chem 1999;274: 11408-16.
43. Chatterjee M, Sequeira L, Jenkins-Kabaila M, Dubyk CW, Pathak S, van Golen KL. Individual rac GTPases mediate aspects of prostate cancer cell and bone marrow endothelial cell interactions. J Signal Transduct 2011;2011:541851.
44. Soulitzis N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006;29:305-14.
45. Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2009;21:41-8.
46. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, et al. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phe-notype in three dimensional cultures and in vivo. Cancer Res 2006;66:1526-35. (Pubitemid 43259934)
47. Cress AE, Rabinovitz I, Zhu W, Nagle RB. The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev 1995;14:219-28.
48. Sroka IC, Anderson TA, McDaniel KM, Nagle RB, Gretzer MB, Cress AE. The laminin binding integrin alpha6beta1 in prostate cancer peri-neural invasion. J Cell Physiol 2010;224:283-8.
49. Gan HK, Burgess AW, Clayton AH, Scott AM. Targeting of a con-formationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 2012;72:2924-30.
50. Wirth M, Heidenreich A, Gschwend JE, Gil T, Zastrow S, Laniado M, et al. A multicenter phase I study of DI17E6, a novel de-immunized monoclonal antibody to human av integrins, in progressive castrate-resistant prostate cancer (CRPC) with bone metastases after chemotherapy. J Clin Oncol 2011;29 suppl; abstr e15060.
51. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 2010;16:1414-20.
52. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012;481:85-9.
53. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a meta-static niche component to colonize the lungs. Nat Med 2011;17: 867-74.
54. Kostenuik PJ, Sanchez-Sweatman O, Orr FW, Singh G. Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin Exp Metastasis 1996;14: 19-26. (Pubitemid 26008958)
55. Hall CL, Dai J, van Golen KL, Keller ET, Long MW. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 2006;66: 8648-54. (Pubitemid 44449180)